SM
RVPH

Sabby Management’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Sabby Management’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-55
Closed -$536K – 82
2023
Q3 		$536K Sell
55
-62
-53% -$5.78K 0.39% 12
2023
Q2 		$1.37M Buy
117
+111
+1,850% +$14.1K 1.12% 6
2023
Q1 		$46.1K Buy
+6
New +$524 0.04% 74

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Sabby Management's RVPH Position: Q3 2025 in Review

Sabby Management sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q3 2025, closing a stake of 8,496 shares — an estimated $72.2K sold.

Sabby Management first reported a position in RVPH in Q4 2020 and held it in 8 quarters. The position peaked at $3.13M in Q4 2020. 42 funds tracked by Wall St. Rank hold RVPH as of Q3 2025.

  • Sabby Management reported no remaining REVIVA PHARMA HLDGS INC position as of Q3 2025 after selling out during the quarter.
  • Sabby Management sold 8,496 REVIVA PHARMA HLDGS INC shares in Q3 2025, an estimated $72.2K.
  • Sabby Management first reported a position in REVIVA PHARMA HLDGS INC in Q4 2020 and held it in 8 quarters.
  • Sabby Management's REVIVA PHARMA HLDGS INC position peaked at $3.13M in Q4 2020.
  • 42 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2025.

Based on Sabby Management's 13F filing for Q3 2025, filed 14 Nov 2025.